Humana Stock Drops Over 5% as Firm Pulls Guidance
Image courtesy of

Humana Stock Drops Over 5% as Firm Pulls Guidance

Humana withdrew its 2025 guidance due to Medicare Advantage uncertainties. Stock dropped over 5%.
Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

Health insurance giant Humana Inc. (NYSE: HUM) saw its stock price plummet by more than 5% on Wednesday after the company withdrew its financial guidance for the year 2025. The decision to pull the guidance was attributed to uncertainties surrounding federal rate adjustments for Humana’s core Medicare Advantage business, which plays a crucial role in the company’s operations and overall performance.

Humana Beats EPS Expectations for Q1

Despite the setback, Humana beat earnings expectations for the first quarter of 2024, reporting an adjusted earnings per share (EPS) of $7.23, surpassing the FactSet consensus estimate of $6.12. However, the company’s net income for the quarter declined to $1.01 billion from $1.61 billion a year ago, indicating a decrease in profitability compared to the previous year.

Despite earlier warnings that higher medical costs could negatively impact future results, Humana has successfully kept its medical costs in line with projections. The company’s ability to manage these costs effectively has been a positive factor amidst the uncertainty surrounding the Medicare Advantage business.

Humana Stock Down 36%+ Over the Past Year

Looking ahead, Humana remains optimistic about the long-term performance of its Medicare business but has cautioned investors about potential challenges and the need for a recovery period to stabilize margins at 3% or higher.

The company’s leadership team is actively working on strategies to navigate the evolving healthcare landscape and maintain a strong market position.

At the time of writing, Humana’s stock price stood at $311.28, reflecting the recent 5.09% decline. Over the past year, the company’s stock has underperformed significantly, with a decline of 36.10% compared to a 22.50% increase in the S&P 500.

Despite the recent volatility, Humana has a beta of approximately 0.74, indicating lower volatility compared to the broader market, and a Price/Earnings (TTM) ratio of around 16.40, suggesting a relatively reasonable valuation in the context of the healthcare sector.

Do you think the market is reacting appropriately to the news? Let us know in the comments below.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.